Search

everythinglearnresearchcommunity

for

Search:↓

A phase 3 trial for Breezula (clascoterone solution) to treat male pattern hair loss has been listed, with 726 participants and a completion date of January 2025. Other treatments mentioned include Aneira Pharma's combination of minoxidil and latanoprost, Triple Hair's combination of minoxidil, latanoprost, and finasteride, and a new microneedling and LLLT device called StimuSIL.

Testing the effectiveness of Verteporfin as a potential treatment for hair loss, with users discussing their thoughts on its long-term results. Treatments mentioned include Minoxidil, Finasteride, and RU58841.

User discusses a promising topical Procyanidin B2 treatment for hair loss. Users share mixed experiences and mention effective treatments like finasteride, minoxidil, and LLLT.

Ecklonia cava is suggested as an alternative to finasteride and dutasteride for hair growth, potentially offering benefits without their side effects. It is promoted for anti-aging, mood enhancement, and cognitive support.

The conversation is about sourcing gray market compounds, gt20029 and pp405, for hair loss treatment. The user is interested in these compounds despite their unproven status and potential risks.

IGFBP‐rP1 shows potential for treating androgenic alopecia by influencing hair cycle transitions. Increasing IGF-1 levels may have similar effects to Minoxidil and 5-AR inhibitors in reducing hair loss.

Clascoterone 5% shows promising hair growth results but is criticized for high cost and unclear effectiveness compared to other treatments like finasteride. Glenmark is testing a combination of Clascoterone 7.5% and Minoxidil 5% in India.

A fake hair loss product called "PP405" is being humorously discussed, with users joking about its effectiveness and availability on resale websites. The consensus is that it's a scam, with some users sarcastically claiming miraculous results.

A potential treatment for alopecia involving a protein that calms hair follicles has shown promise in rats, but skepticism remains about its applicability to humans. Many users express doubt about the timeline for effective hair loss treatments, comparing it to past unfulfilled promises.

ABS-201, a prolactin receptor blocker, shows promise in reversing hair loss and graying, with early success in macaques. Current treatments like finasteride, minoxidil, and RU58841 are still widely used, but new options like PP405 are eagerly anticipated.

Minoxidil is highly toxic to cats, and users are advised to avoid using it if they have cats, or to take extreme precautions if they do. Some users suggest using oral minoxidil instead, but it may not be available in all countries.

A user discusses using a serum called Dallixa, containing minoxidil-like and bimatoprost-like compounds, for hair loss and greying. The user's dermatologist advised against finasteride and suggested the serum might improve hair pigmentation.

The user is seeking advice on a hair loss treatment called Ell Cranell, which contains Alfatradiol. Another user shared information from a study stating that Alfatradiol only slows down or stabilizes hair loss, but does not increase hair density or thickness.

The user has been using finasteride for two years without results and recently started a new routine involving derma stamping, retinol, and minoxidil, which seems to show progress. The user microneedles about half the week and uses L’Oréal night serum for retinol.

The user showed a one-year hair regrowth progress using finasteride only, after stopping minoxidil due to its toxicity to cats. They noticed hair growth around six or seven months into treatment.

The user started using a hair loss treatment called pyrilutamide and experienced mild chest discomfort and tightness, similar to previous side effects from RU58841. They plan to reduce the dosage due to these side effects and will provide an update on the results in 1-2 months.

PP405 may damage hair follicles if used long-term, suggesting cycling might be necessary. Combining it with finasteride could help maintain hair growth.

PP405 is in phase 2 trials for hair loss, with discussions on its cost and effectiveness compared to minoxidil and finasteride. Users are skeptical about its efficacy and timeline, with hopes for market release by 2027.

The conversation discusses the potential market release of a hair loss treatment called GT20029 by Anageninc, with users expressing interest and discussing the importance of safety and effectiveness. Some users plan to contact Anageninc to show demand for the product.

Anageninc stopping the sale of Pyrilutamide due to a cease and desist order from Kintor, with some speculating that it was either a hoax or subpar product.

The conversation is about a user's hair loss treatment regimen, which includes Dutasteride, oral Minoxidil, topical Dutasteride, Minoxidil sulfate, antioxidants, and various supplements. The user is also using a derma stamp and has paused Tretinoin due to a TCA peel recovery.

Someone looking for solutions to their hair loss, who has tried and failed to tolerate anti-androgen treatments such as finasteride, CB-03-01, RU58841, and Eucapil. The user is seeking advice and understanding of their extreme sensitivity to these treatments.

The conversation is about whether the phase 2 results for pyrilutamide, a potential hair loss treatment, were presented at a dermatology convention and inquiries about the completion of phase 3 trials. Specific treatments mentioned include pyrilutamide.

The conversation discusses using Bimatoprost for eyebrow regrowth and its potential use on the hairline, with concerns about cost and side effects. Alternatives like topical Minoxidil are mentioned, but the user is worried about aging and acne.

Verteporfin is being explored for hair regeneration, with unofficial trials and updates shared online. Efforts are being made to encourage more surgeons to trial verteporfin for donor hair regeneration.

The conversation discusses the effectiveness and value of a Locklabs pill containing finasteride, minoxidil, biotin, and a low dose of dutasteride for hair loss. The user is uncertain if the .1mg dutasteride dosage is sufficient and worth the cost.

User tried various hair loss treatments with limited success. RU58841 was effective but caused side effects, now trying Eucapil and continuing Finasteride.

CRISPR treatments for blood disorders have been approved, leading to discussions about its potential for treating hair loss (AGA). A study showed that editing a gene related to DHT sensitivity could lead to hair regrowth, suggesting CRISPR may eventually be used for AGA, but it's expected to be expensive and not soon available.

PP405 shows potential for hair growth, with 31% of advanced balding men experiencing over 20% increase in hair density in 8 weeks. However, skepticism persists due to selective data presentation and lack of long-term results, with comparisons to treatments like minoxidil and finasteride.

A South Korean company, Therazyne, has developed a promising hair loss treatment using a WNT chain surrogate that binds to Frizzled 7, with human follicle testing expected soon. Current treatments like minoxidil and finasteride are not seen as cures, and while optimism exists for future solutions like PP405, approval processes are lengthy.